Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone)

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 1330-1342

  Chen, Chi ^a   Meng, Linghua ^a   Ma, Xiaochao ^a   Krausz, Kristopher W ^a   Pommier, Yves ^a   Idle, Jeffrey R ^b   Gonzalez, Frank J ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 6,8 DIFLUORO 2 (3 FLUOROPHENYL) 7 METHYL 4H 1 BENZOPYRAN 4 ONE; AMINOFLAVONE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 1A2; DIHYDROXY AMINOFLAVONE; DRUG METABOLITE; GLUCURONIDE; MONOHYDROXY AMINOFLAVONE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; LIQUID CHROMATOGRAPHY; MICROSOME; MOUSE; NONHUMAN; OXIDATION KINETICS; PRIORITY JOURNAL; SPECIES COMPARISON; TANDEM MASS SPECTROMETRY; TUMOR CELL; URINARY EXCRETION;

EID: 33747584882     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.105213     Document Type: Article

References (29)

1. Akama T, Ishida H, Kimura U, Gomi K, and Saito H (1998) Structure-activity relationships of the 7-substituents of 5,4′-diamino-6, 8,3′-trifluoroflavone, a potent antitumor agent. J Med Chem 41:2056-2067.
2. Akama T, Ishida H, Shida Y, Kimura U, Gomi K, Saito H, Fuse E, Kobayashi S, Yoda N, and Kasai M (1997) Design and synthesis of potent antitumor 5,4′-diaminoflavone derivatives based on metabolic considerations. J Med Chem 40:1894-1900.
3. Akama T, Shida Y, Sugaya T, Ishida H, Gomi K, and Kasai M (1996) Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem 39:3461-3469.
4. Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S, and Gonzalez FJ (1996) Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics 6:291-296.
5. Butler MA, Iwasaki M, Guengerich FP, and Kadlubar FF (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
6. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, Nebert DW, Idle JR, and Gonzalez FJ (2005) Differential metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 18:1471-1478.
7. Gonzalez FJ (2003) Role of gene knockout and transgenic mice in the study of xenobiotic metabolism. Drug Metab Rev 35:319-335.
8. Guengerich FP (2005) Human Cytochrome P450 Enzymes, in Cytochrome P450-Structure, Mechanism, and Biochemistry (Montellano PROd, ed) pp 377-463, Kluwer Academic/Plenum Publishers, Dordrecht, The Netherlands.
9. Havsteen BH (2002) The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96:67-202.
10. Kaderlik KR, Mulder GJ, Turesky RJ, Lang NP, Teitel CH, Chiarelli MP, and Kadlubar FF (1994) Glucuronidation of N-hydroxy heterocyclic amines by human and rat liver microsomes. Carcinogenesis 15:1695-1701.
11. Kadlubar FF, Miller JA, and Miller EC (1977) Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res 37:805-814.
12. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, and Ames MM (2002) Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 62:143-153.
13. Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, et al. (2004a) Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 3:715-725.
14. Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, and Vistica DT (2004b) Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1. J Urol 171:1688-1697.
15. Meng LH, Kohlhagen G, Liao ZY, Antony S, Sausville E, and Pommier Y (2005) DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 65:5337-5343.
16. Meng LH, Shankavaram U, Chen C, Agama K, Fu H, Gonzalez FJ, Weinstein J, and Pommier Y (2006) Activation of aminoflavone (NSC 626288) by a sulfotransferase is required for the drug's antiproliferative effect and for induction of histone-H2AX. Cancer Res, in press.
17. Mullen W, Graf BA, Caldwell ST, Hartley RC, Duthie GG, Edwards CA, Lean ME, and Crozier A (2002) Determination of flavonol metabolites in plasma and tissues of rats by HPLC-radiocounting and tandem mass spectrometry following oral ingestion of [2-(14)C]quercetin-4′-glucoside. J Agric Food Chem 50:6902-6909.
18. Otake Y and Walle T (2002) Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab Dispos 30:103-105.
19. Phillips LR, Bramhall C, Buckley J, Wolfe T, House TL, and Stinson SF (2000) Identification of the principal circulating metabolite of a synthetic 5,4′-diaminoflavone (NSC 686288), an antitumor agent, in the rat. J Chromatogr B Biomed Sci Appl 741:205-211.
20. Pineau T, Fernandez-Salguero P, Lee SS, McPhail T, Ward JM, and Gonzalez FJ (1995) Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci USA 92:5134-5138.
21. Pobst LJ and Ames MM (2006) CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines. Cancer Chemother Pharmacol 57:569-576.
22. Saito K, Yamazoe Y, Kamataki T, and Kato R (1985) Fast-atom bombardment and electron-impact mass spectrometry of N-hydroxyarylamines, active intermediates of mutagenic aromatic amines. Xenobiotica 15:327-332.
23. Shimada T, Yamazaki H, Mimura M, Wakamiya N, Ueng YF, Guengerich FP, and Inui Y (1996) Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 24:515-522.
24. Turesky RJ (2002) Heterocyclic aromatic amine metabolism, DNA adduct formation, mutagenesis, and carcinogenesis. Drug Metab Rev 34:625-650.
25. Turesky RJ, Guengerich FP, Guillouzo A, and Langouet S (2002) Metabolism of heterocyclic aromatic amines by human hepatocytes and cytochrome P4501A2. Mutat Res 506-507:187-195.
26. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (1999) CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor. Drug Metab Dispos 27:1519-1522.
27. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science (Wash DC) 275:343-349.
28. Yamauchi A, Ueda N, Hanafusa S, Yamashita E, Kihara M, and Naito S (2002) Tissue distribution of and species differences in deacetylation of N-acetyl-L-cysteine and immunohistochemical localization of acylase I in the primate kidney. J Pharm Pharmacol 54:205-212.
29. Yu AM, Idle JR, Krausz KW, Kupfer A, and Gonzalez FJ (2003) Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305:315-322.